Pmh26 the Cost Burden of Treatment Resistance in Patients With Depression

Gibson, TB; 杨静,; Carls, GS; Kim, E; Bagalman, JE; Wn, Burton; Tran, QV; Pikalov, A.; Goetzel, RZ

doi:10.1016/s1098-3015(10)73947-4

Cited by 77 publications

(119 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Additionally, non-steroidal anti-inflammatory drugs might be beneficial as adjunctive treatments in unipolar (Akhondzadeh et al, 2009;Muller et al, 2006) and bipolar (Nery et al, 2008) disorders and the TNFα antagonist infliximab may particularly benefit depressed individuals with a history of treatment resistance and high inflammation (Raison et al, 2013). Treatment non-response contributes greatly to the burden of affective illnesses (Gibson et al, 2010); it is common, affecting at least a third of patients (Warden et al, 2007), and is generally associated with poorer long-term outcomes (Fekadu et al, 2009). To improve the rate and robustness of clinical response in depression there is a need for novel treatment strategies (Kupfer et al, 2012), including enhancing the personalisation of treatment provision using stratification.…”

Section: Introductionmentioning

confidence: 99%

Inflammation and clinical response to treatment in depression: A meta-analysis

Strawbridge

Arnone

Danese

et al. 2015

European Neuropsychopharmacology

510

366

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Inflammation and clinical response to treatment in depression: A meta-analysis

Strawbridge

Arnone

Danese

et al. 2015

European Neuropsychopharmacology

510

366

View full text Add to dashboard Cite

“…Fully or partially capitated plans include health maintenance organization plans and POS plans with capitation [19]. This database has been used extensively in studies of medical expenditures of many medical conditions [8,[20][21][22].…”

Section: Data Sourcementioning

confidence: 99%

Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008

Shrestha

Zhang

et al. 2013

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Aim-We aimed at estimating excess medical expenditures associated with major depressive disorder (MDD) among working-age adults diagnosed with diabetes, disaggregated by treatment mode: insulin-treated diabetes (ITDM) or non-insulin-treated diabetes (NITDM).Methods-We analyzed data for over 500,000 individuals with diagnosed diabetes from the 2008 U.S. MarketScan claims database. We grouped diabetic patients first by treatment mode (ITDM or NITDM), then by MDD status (with or without MDD), and finally by whether those with MDD used antidepressant medication. We estimated annual mean excess outpatient, inpatient, prescription drug, and total expenditures using regression models, controlling for demographics, types of health coverage, and comorbidities.Results-Among persons having ITDM, the estimated annual total mean expenditure for those with no MDD (the comparison group) was $19,625. For those with MDD, the expenditures were $12,406 (63%) larger if using antidepressant medication and $7322 (37%) larger if not using antidepressant medication. Among persons having NITDM, the corresponding estimated expenditure for the comparison group was $10,746, the excess expenditures were $10,432 (97%) larger if using antidepressant medication and $5579 (52%) larger if not using antidepressant medication, respectively. Inpatient excess expenditures were the largest of total excess expenditure for those with ITDM and MDD treated with antidepressant medication; for all others with diabetes and MDD, outpatient expenditures were the largest excess expenditure.Conclusions-Among working-age adults with diabetes, MDD was associated with substantial excess medical expenditures. Implementing the effective interventions demonstrated in clinical trials and treatment guidelines recommended by professional organizations might reduce the economic burden of MDD in this population.

show abstract

“…After three subsequent trials designed to evaluate the efficacy of various switch and ' add-on ' strategies, 33% of patients had failed to achieve remission (Warden et al, 2007), conveying the high prevalence of TRD. The inevitable consequence of TRD is a substantial societal and economic impact, with a cost burden that is approximately twice that of non-resistant MDD (Gibson et al, 2010;Ivanova et al, 2010).…”

Section: Treatment Resistant Depressionmentioning

confidence: 99%

Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation

Rizvi

Donovan

Giacobbe

et al. 2011

International Review of Psychiatry

View full text Add to dashboard Cite

Antidepressant treatments, including pharmacotherapy and psychotherapy, do not result in remission for the majority of patients with major depressive disorder. The high prevalence of treatment resistant depression (TRD) poses a significant issue for patients as well as both societal and economic costs. Due to the limited efficacy of existing therapies in this sub-population, alternative somatic treatments are being explored. Both vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are neurostimulation treatments for TRD. While VNS has Food Drug Administration approval as an adjunctive therapy for MDD, DBS is still in the experimental stages. This article will review the evidence supporting the clinical utility of these therapies.

show abstract

Pmh26 the Cost Burden of Treatment Resistance in Patients With Depression

Cited by 77 publications

References 0 publications

Inflammation and clinical response to treatment in depression: A meta-analysis

Inflammation and clinical response to treatment in depression: A meta-analysis

Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008

Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation

Contact Info

Product

Resources

About